Fig. 8

In vivo kinetics of different PARP inhibitors. a JHU-LX48 SCLC PDX bearing mice (n = 3/group, 15 groups, 45 mice total) were injected (i.v.) first with olaparib (50 mg/kg) or talazoparib (0.3 mg/kg). Mice were injected (i.v.) with 200–300 µCi of [¹⁸F]PARPi 1, 2, 4, 8, 24, or 48 h later, and imaged via PET/CT 2 h post [¹⁸F]PARPi injection. b Representative coronal slices from 4 different time points after olaparib (left) and talazoparib (right) administration. c Quantification of PET images for tumor uptake at each of 6 different time points represented as a percentage of blocked signal. Error bars represent the SD